Business
A jury found that Takeda Pharmaceuticals U.S.A. and Eli Lilly & Co. did not disclose cancer risks for their diabetes medicine, Actos. Previous judgments have been thrown out on appeal.
April 8, 2014
Drugmakers Takeda Pharmaceutical Co. and Eli Lilly & Co. were ordered to pay a total of $9 billion in punitive damages after a Louisiana jury decided the companies did not disclose cancer risks of their diabetes medicine Actos.
Takeda, Eli Lilly must pay $9 billion in punitive damages over Actos
Japanese firms investing in California biotechs
Dec. 26, 2009
Takeda Pharmaceutical Co. said Monday that it would acquire Syrrx Inc., a privately held California biotechnology company working on treatments for cancer and diabetes.
Feb. 8, 2005
Takeda Pharmaceutical Co. and Eli Lilly & Co. had a $9-billion punitive damage award over claims that the drug makers hid the cancer risks of their Actos diabetes medicine sharply reduced.
Oct. 27, 2014
The deal with Takeda will help offset the loss of revenue elsewhere.
Feb. 5, 2008
Japan’s aging population is providing Japanese drug makers a golden opportunity to develop and market new drugs, giving them an edge over more aggressive foreign rivals.
Nov. 10, 1987
TOKYO — A U.S. jury ordered Japanese drugmaker Takeda Pharmaceutical Co. and its U.S. counterpart, Eli Lilly and Co., to pay $9 billion in punitive damages over a diabetes medicine linked to cancer.
Science & Medicine
Amgen lung cancer drug fails in late-stage study
March 30, 2011